CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet needs in cancer treatment. The company's website is www.cytomx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CytomX Therapeutics, Inc. does
In the company’s own words
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet needs in cancer treatment. The company's website is www.cytomx.com.
CytomX has pioneered the PROBODY platform, a versatile, multi-modality technology for creating conditionally activated, masked biologics. The platform is built on deep expertise in tumor biology and tumor-associated enzymes called proteases. The masking strategy is designed to reduce binding of biologic therapeutics to their targets until the mask is removed by proteases in the tumor microenvironment, providing more selective tumor targeting and optimizing the therapeutic index of clinical candidates.
The company's lead clinical program is varsetatug masetecan (Varseta-M), an investigational antibody-drug conjugate targeting epithelial cell adhesion molecule (EpCAM) and initially focused on colorectal cancer. Varseta-M is armed with a topoisomerase-1 inhibitor payload and is currently in Phase 1 clinical development. The company's second clinical program is CX-801, an investigational masked version of interferon alpha-2b currently in Phase 1 trials for advanced melanoma, with evaluation in combination with checkpoint inhibitors.
CytomX's pipeline spans preclinical and clinical programs across multiple therapeutic formats including antibody-drug conjugates, T-cell engagers, immunotherapies, and mRNA-based approaches. The company has established strategic alliances with major multinational pharmaceutical companies including Amgen, Bristol Myers Squibb, Astellas Pharma, Regeneron Pharmaceuticals, and Moderna to advance PROBODY therapeutic candidates.
The company's intellectual property portfolio includes at least 245 granted patents and at least 300 pending patent applications as of January 2026. CytomX has treated more than 500 patients with diverse tumor types across multiple clinical studies, providing clinical proof of concept and a knowledge base for advancing its platform technology and drug candidates. The company operates as a clinical-stage enterprise with no approved products generating revenue from product sales.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1501989
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CytomX Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CytomX Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CytomX Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CytomX Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CytomX Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”